Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Gains from Sales and Divestitures (2023 - 2025)

Historic Gains from Sales and Divestitures for Harmony Biosciences Holdings (HRMY) over the last 3 years, with Q3 2025 value amounting to $215795.0.

  • Harmony Biosciences Holdings' Gains from Sales and Divestitures rose 5984.81% to $215795.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $215795.0, marking a year-over-year increase of 5984.81%. This contributed to the annual value of $135000.0 for FY2024, which is 35000.0% up from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Gains from Sales and Divestitures stood at $215795.0, which was up 5984.81% from $170795.0 recorded in Q2 2025.
  • Harmony Biosciences Holdings' 5-year Gains from Sales and Divestitures high stood at $215795.0 for Q3 2025, and its period low was $15000.0 during Q1 2024.
  • For the 3-year period, Harmony Biosciences Holdings' Gains from Sales and Divestitures averaged around $84373.7, with its median value being $30000.0 (2023).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first plummeted by 5000.0% in 2024, then skyrocketed by 103863.33% in 2025.
  • Quarter analysis of 3 years shows Harmony Biosciences Holdings' Gains from Sales and Divestitures stood at $30000.0 in 2023, then surged by 350.0% to $135000.0 in 2024, then soared by 59.85% to $215795.0 in 2025.
  • Its Gains from Sales and Divestitures was $215795.0 in Q3 2025, compared to $170795.0 in Q2 2025 and $121521.0 in Q1 2025.